Gastric cancer with impaired DNA unpaired nucleotide repair system

D.V. Rianzhin

Dr. Berzin Medical Institute

ORCID: 0000-0001-5802-7861

G.A. Raskin

Dr. Berezin Medical Institute;
Saint-Petersburg State University

ORCID: 0000-0002-7522-6552

M.S. Mukhina

Dr. Berezin Medical Institute

ORCID: 0000-0002-3735-6145

I.V. Rykov

Saint Petersburg Hospital of Russian Academy of Sciences

ORCID: 0000-0002-8250-8144

S.O. Kusin

Saint Petersburg Hospital of Russian Academy of Sciences

ORCID: 0000-0002-0524-6582

O.V. Khodyreva

Saint-Petersburg State Research Institute of Phthisiopulmonology

ORCID: 0000-0001-8437-4891

Gastric cancer with impaired DNA unpaired nucleotide repair system

Authors:

D.V. Rianzhin, G.A. Raskin, M.S. Mukhina, I.V. Rykov, S.O. Kusin, O.V. Khodyreva

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(2): 44‑47

DOI: 10.17116/patol20238502144

Downloaded: 4

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Rianzhin DV, Raskin GA, Mukhina MS, Rykov IV, Kusin SO, Khodyreva OV. Gastric cancer with impaired DNA unpaired nucleotide repair system. Russian Journal of Archive of Pathology. 2023;85(2):44‑47. (In Russ.)
https://doi.org/10.17116/patol20238502144

Доказательная гастроэнтерология: pro et contra

Актуальные вопросы педиатрической практики

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Study of FGFR2 status in gastric cancer by immunohistochemistry and fluorescent in situ hybridization. Russian Journal of Archive of Pathology. 2023;(3):40-45

Prognostic significance of PD-L1 expression as a potential predictor of survival in gastric cancer. Russian Journal of Archive of Pathology. 2023;(4):18-23

E-cadherin: structure and functions, role in gastric cancer carcinogenesis. Russian Journal of Archive of Pathology. 2023;(4):70-77

Assessment of HER2 status of carcinomas of various localizations. Russian Journal of Archive of Pathology. 2023;(6):31-46

The choice of a method for the correction of pyloric tumor stenosis. P.A. Herzen Journal of Oncology. 2023;(2):66-76

Simultaneous surgery for upper gastrointestinal cancer and cardiovascular diseases. Pirogov Russian Journal of Surgery. 2023;(7):29-36

Characteristics of the phagocytic component of the immune system in early-stage gastric cancer. P.A. Herzen Journal of Oncology. 2023;(4):30-34

The significance of the tumor microenvironment and molecular biological parameters in assessing the prognosis of the disease in patients with early-stage gastric cancer. P.A. Herzen Journal of Oncology. 2023;(4):78-85

Neoadjuvant chemotherapy with FOLFIRINOX regimen for resectable gastric cancer: immediate results. P.A. Herzen Journal of Oncology. 2023;(5):5-12

This article presents a case of successful treatment of inoperable gastric cancer with impaired mismatched nucleotide repair system (dMMR/MSI-H) in a 72-year-old patient. In view of age, somatic status and the presence of comorbidity, it was decided to prescribe anti-PD-1 therapy in the 1st line of treatment. Currently, after a 2-year course of treatment, the patient is in stable remission.

Keywords:

gastric cancer

mismatch repair deficiency

anti-PD-1 therapy

Authors:

D.V. Rianzhin

Dr. Berzin Medical Institute

ORCID: 0000-0001-5802-7861

G.A. Raskin

Dr. Berezin Medical Institute;
Saint-Petersburg State University

ORCID: 0000-0002-7522-6552

M.S. Mukhina

Dr. Berezin Medical Institute

ORCID: 0000-0002-3735-6145

I.V. Rykov

Saint Petersburg Hospital of Russian Academy of Sciences

ORCID: 0000-0002-8250-8144

S.O. Kusin

Saint Petersburg Hospital of Russian Academy of Sciences

ORCID: 0000-0002-0524-6582

O.V. Khodyreva

Saint-Petersburg State Research Institute of Phthisiopulmonology

ORCID: 0000-0001-8437-4891

Received:

24.09.2022

Accepted:

21.12.2022

List of references:

International Agency for Research on Cancer. World Health Organization. GLOBOCAN 2020. Stomach. https://gco.iarc.fr/today/data/factsheets/cancers/7-Stomach-fact-sheet.pdf
Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, Walsh-Vockley C, Petersen GM, Walsh MD, Leggett BA, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20(4):1043-1048. https://doi.org/10.1200/JCO.2002.20.4.1043
Ratti M, Lampis A, Hahne JC, Passalacqua R, Valeri N. Microsatellite instability in gastric cancer: molecular bases, clinical perspectives, and new treatment approaches. Cell Mol Life Sci. 2018;75(22):4151-4162. https://doi.org/10.1007/s00018-018-2906-9
Ajani JA, D’Amico TA, Bentrem DJ, Chao J, Cooke D, Corvera C, Das P, Enzinger PC, Enzler T, Fanta P, et al. Gastric cancer, version 2.2022, NCCN clinical practice guidelines on oncology. J Natl Compr Canc Netw. 2022;20(2):167-192. https://doi.org/10.6004/jnccn.2022.0008
Bang YJ, Van Cutsem E, Fuchs CS, Ohtsu A, Tabernero J, Ilson DH, Hyung WJ, Strong VE, Goetze TO, Yoshikawa T, et al. KEYNOTE-585: phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019;15(9):943-952. https://doi.org/10.2217/fon-2018-0581
Rasmussen L, Arvin A. Chemotherapy-induced immunosuppression. Environ Health Perspect. 1982;43:21-25. https://doi.org/10.1289/ehp.824321
Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, Fassan M, Rugge M, Valeri N, Okines A, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the medical research council adjuvant gastric infusional chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3(9):1197-1203. https://doi.org/10.1001/jamaoncol.2016.6762
Tabernero J, Van Cutsem E, Bang YJ, Fuchs CS, Wyrwicz L, Lee KW, Kudaba I, Garrido M, Chung HC, Castro H, et al. Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: the phase III KEYNOTE-062 study. J Clin Oncol. 2019;37(18 suppl):LBA4007. https://doi.org/10.1200/JCO.2019.37.18_suppl.LBA4007

Close metadata